Vertex Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to Vertex Reports Third Quarter 2015 Financial Results
October 29, 2015 7:56 AM EDT
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and boosted his price target on Vertex (NASDAQ: VRTX) to $180.00 (from $163.00) following solid Q3 results with KALYDECO and ORKAMBI both beating.
Tenthoff commented, "Over 3,000 patients began ORKAMBI in 3Q:15 resulting in sales of $130.8 million,... More
October 29, 2015 6:58 AM EDT
Baird analyst Brian Skorney reiterated an Outperform rating and $160 price target on Vertex (NASDAQ: VRTX) following results saying they are bullish on first quarter of Orkambi sales.
Skorney commented, "Right off the bat, Orkambi commanded ~35% of the patients eligible for treatment, according... More
October 28, 2015 4:02 PM EDT
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of ($0.39), $0.09 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $309.8 million versus the consensus estimate of $245.84 million.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
...
More
